Good
Mostly Aligned
Patient Risk:
Low
Summary
Dosing and safety statements align with the label; key dosing is supported and warnings/drug interactions are covered. Omissions include contraindications, pregnancy and pediatric information, and cost/generic/patient assistance language.
Category Scores
Accurate Statements
Typical maintenance dosing is 75 mg once daily.
2
Your exact dose and duration should come from your clinician.
2
Do not start or stop taking Plavix on your own.
5
It can increase bleeding risk, especially with NSAIDs (e.g., ibuprofen, naproxen), aspirin, anticoagulants, or in people with upcoming surgeries.
5
Some drug interactions (e.g., certain proton pump inhibitors) may affect its effectiveness—discuss all medications with your doctor.
7
Unsupported Statements
Plavix (clopidogrel) 75 mg is a prescription antiplatelet medication.
Not stated in available label sections; no explicit Rx-only language.
It can’t be legally bought without a prescription in most places.
Not addressed in provided label sections.
If cost or access is issue, ask your doctor about generic clopidogrel (the same medication in generic form).
Not addressed in provided label sections.
If cost or access is an issue, ask your doctor about patient assistance programs and insurance coverage.
Not addressed in provided label sections.
Contradictions
Important Omissions
Pregnancy risk information (8.1), and Pediatric use (8.4) safety data.
Importance:
High
Contraindications details (Section 4).
Importance:
High
Cost/generic/patient assistance information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label notes increased bleeding risk with antiplatelet therapy; general risk described without patient-specific quantification.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing contraindication and population safety details; omissions on generic/patient assistance language.
Suggested Improvement
Add explicit contraindication language from label section 4; include pregnancy (8.1) and pediatric use (8.4) safety summaries; consider cost/generic/patient assistance statements only if present in labeling.